Funder: National Institutes of Health

Due Dates: June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision) | September 7, 2025 (AIDS) | October 5, 2025 (New) | November 5, 2025 (Renewal/Resubmission/Revision) | January 7, 2026 (AIDS) | February 5, 2026 (New) | March 5, 2026 (Renewal/Resubmission/Revision) | May 7, 2026 (AIDS)

Funding Amounts: Up to $200,000 direct costs per year for up to 3 years (R01); total program intent is $1M/year for up to 3 awards beyond normal R01s.

Summary: Funds small, short-term clinical trials in humans to generate preliminary and feasibility data for future, larger trials on diseases within the NIDDK mission.

Key Information: Preliminary efficacy data are not required; only clinical trials (not observational studies) are eligible; contact NIDDK staff early to confirm fit.